Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 2
2005 2
2006 1
2008 1
2016 1
2017 2
2018 2
2020 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
IMPDH inhibition activates TLR-VCAM1 pathway and suppresses the development of MLL-fusion leukemia.
Liu X, Sato N, Yabushita T, Li J, Jia Y, Tamura M, Asada S, Fujino T, Fukushima T, Yonezawa T, Tanaka Y, Fukuyama T, Tsuchiya A, Shikata S, Iwamura H, Kinouchi C, Komatsu K, Yamasaki S, Shibata T, Sasaki AT, Schibler J, Wunderlich M, O'Brien E, Mizukawa B, Mulloy JC, Sugiura Y, Takizawa H, Shibata T, Miyake K, Kitamura T, Goyama S. Liu X, et al. Among authors: iwamura h. EMBO Mol Med. 2023 Jan 11;15(1):e15631. doi: 10.15252/emmm.202115631. Epub 2022 Dec 1. EMBO Mol Med. 2023. PMID: 36453131 Free PMC article.
Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes.
Garcia-Manero G, Pemmaraju N, Alvarado Y, Naqvi K, Ravandi F, Jabbour E, De Lumpa R, Kantarjian H, Advani A, Mukherjee S, Gerds A, Carraway HE, Nazha A, Iwamura H, Murase M, Bavisotto L, Kurman M, Maier G, Johansen M, Sekeres MA. Garcia-Manero G, et al. Among authors: iwamura h. Leuk Lymphoma. 2020 Aug;61(8):1943-1953. doi: 10.1080/10428194.2020.1747065. Epub 2020 Apr 7. Leuk Lymphoma. 2020. PMID: 32264726 Clinical Trial.
FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells.
Mima S, Kakinuma C, Higuchi T, Saeki K, Yamada T, Uematsu R, Ishino M, Kito N, Nishikawa H, Kuniyoshi H, Matsumoto T, Fujiwara H, Paradiso LJ, Shimada Y, Iwamura H. Mima S, et al. Among authors: iwamura h. J Pharmacol Exp Ther. 2018 Jul;366(1):125-135. doi: 10.1124/jpet.118.248740. Epub 2018 Apr 13. J Pharmacol Exp Ther. 2018. PMID: 29653962
Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors.
Tatemoto K, Nozaki Y, Tsuda R, Konno S, Tomura K, Furuno M, Ogasawara H, Edamura K, Takagi H, Iwamura H, Noguchi M, Naito T. Tatemoto K, et al. Among authors: iwamura h. Biochem Biophys Res Commun. 2006 Nov 3;349(4):1322-8. doi: 10.1016/j.bbrc.2006.08.177. Epub 2006 Sep 8. Biochem Biophys Res Commun. 2006. PMID: 16979137
Lack of cross-resistance to FF-10501, an inhibitor of inosine-5'-monophosphate dehydrogenase, in azacitidine-resistant cell lines selected from SKM-1 and MOLM-13 leukemia cell lines.
Murase M, Iwamura H, Komatsu K, Saito M, Maekawa T, Nakamura T, Yokokawa T, Shimada Y. Murase M, et al. Among authors: iwamura h. Pharmacol Res Perspect. 2016 Jan 28;4(1):e00206. doi: 10.1002/prp2.206. eCollection 2016 Feb. Pharmacol Res Perspect. 2016. PMID: 26977297 Free PMC article.
14 results